AFFY:OTC-Affymax, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.03

Change

0.00 (0.00)%

Market Cap

USD 2.94M

Volume

4.23K

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Company Website : http://www.affymax.com

Address : 630 Fifth Avenue, New York, NY, United States, 10020

Employees : 2

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 2.39

52 Week High : 0.06

Short Ratio : 2.35

52 Week Low : 0.01

Shorted Shares : 18,481,851

200 Day Moving Average : 0.03

Shorted Shares Previous Month : 15,826,827

50 Day Moving Average : 0.03

Short Percentage : 49.00%

Shares Held by Institutions : 0.02%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-1.19 (-1.73%)

 USD162.57B 24.98 2.76
CSLLY CSL Limited

+0.81 (+0.78%)

 USD94.29B 42.48 24.49
CMXHF CSL Limited

N/A

 USD94.17B 42.37 24.49
GNMSF Genmab A/S

+2.56 (+0.73%)

 USD23.24B 28.18 3.06
UCBJF UCB SA

N/A

 USD22.12B 24.73 18.77
UCBJY UCB SA

-0.67 (-1.15%)

 USD21.92B 24.83 18.77
SBHMY Sino Biopharmaceutical Limited

+1.76 (+8.80%)

 USD21.14B 47.10 3.58
SBMFF Sino Biopharmaceutical Limited

N/A

 USD20.95B 52.75 3.58
PPTDF PeptiDream Inc

N/A

 USD5.30B 260.99 1.36
MPSYF MorphoSys AG

N/A

 USD4.23B 32.27 28.84

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.33% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.33% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 30.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain -66.67% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -66.67% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -12.34% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -12.34% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 51.97% N/A N/A N/A N/A
Risk Adjusted Return -23.75% N/A N/A N/A N/A
Market Capitalization 2.94M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.96 N/A N/A N/A N/A
Price/Book Ratio 0.56 N/A N/A N/A N/A
Price / Cash Flow Ratio N/A N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity 111.59% N/A N/A N/A N/A
Return on Invested Capital N/A N/A N/A N/A N/A
Return on Assets -228.91% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.35 N/A N/A N/A N/A
Short Percent 49.35% N/A N/A N/A N/A
Beta 2.39 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike